Clinical effect of recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein combined with sodium hyaluronate intra-articular injection in the treatment of rheumatoid arthritis
10.3760/cma.j.issn.1008-6706.2019.23.002
- VernacularTitle: 重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合玻璃酸钠关节腔注射治疗类风湿关节炎疗效观察
- Author:
Xiaocong SUN
1
;
Hongling MA
;
Juan ZHAO
;
Yaqi LI
;
Zhipeng XU
;
Xiaoying WANG
;
Min CHEN
Author Information
1. Department of Rheumatology, the Second People′s Hospital of Datong, Datong, Shanxi 037000, China
- Publication Type:Journal Article
- Keywords:
Arthritis, rheumatoid;
Tumor necrosis factor receptor-associated peptides and proteins;
Hyaluronic acid;
Injections, intra-articular;
Randomized controlled trial
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(23):2822-2825
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy of recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein combined with sodium hyaluronate in the treatment of rheumatoid arthritis (RA).
Methods:Forty adult RA patients (12 males, 28 females) aged from 36 to 79 were selected in Department of Rheumatology of the Second People′s hospital of Datong from February 2016 to February 2018.The patients were randomly divided into the observation group and the control group according to the digital table, with 20 cases in each group.The observation group was treated by intra-articular injection of recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein and sodium hyaluronate, and the control group was only treated with recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein.The joint swelling, joint pain, joint mobility, morning stiffness, X-ray grade and total effective rate of the two groups were statistically analyzed before and after treatment.
Results:Before treatment, there were no statistically significant differences in joint swelling, joint pain, joint mobility, morning stiffness, clinical score and X-ray grade between the two groups (all P>0.05). After treatment, the symptoms and signs of the two groups were obviously improved.The joint pain, joint pressure pain, joint activity, morning stiffness and clinical score in the observation group were (1.2±1.2)points, (0.8±0.7)points, (0.5±0.4)points, (0.7±0.7)points and (4.5±2.6)points, respetively, which were significantly better than those in the control group [(2.2±1.4)points, (1.5±0.9)points, (1.5±0.9)points, (1.5±0.6)points and (8.6±4.6)points, U=125, 111, 68, 89 and 97, all P<0.05]. The total effective rate of the observation group was 100% (20/20), while that of the control group was 75% (15/20), there was statistically significant difference between the two groups (χ2=14.10, P<0.01).
Conclusion:The injection of recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein combined with sodium hyaluronate in the treatment of RA can effectively improve the clinical symptoms of RA patients, and it is more effective than single use.It is worthy of popularizing in clinic.
